Short Interest in Akili, Inc. (NASDAQ:AKLI) Declines By 35.4%

Akili, Inc. (NASDAQ:AKLI) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 79,600 shares, a decrease of 35.4% from the March 31st total of 123,200 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Akili

A hedge fund recently bought a new stake in Akili stock. StoneX Group Inc. bought a new position in Akili, Inc. (NASDAQ:AKLI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,064,432 shares of the company’s stock, valued at approximately $518,000. StoneX Group Inc. owned about 1.36% of Akili as of its most recent filing with the Securities and Exchange Commission. 53.12% of the stock is currently owned by hedge funds and other institutional investors.

Akili Stock Performance

NASDAQ:AKLI opened at $0.24 on Friday. The firm’s fifty day simple moving average is $0.28 and its 200 day simple moving average is $0.37. The company has a current ratio of 6.02, a quick ratio of 6.02 and a debt-to-equity ratio of 0.09. Akili has a twelve month low of $0.19 and a twelve month high of $1.67. The firm has a market capitalization of $19.14 million, a price-to-earnings ratio of -0.32 and a beta of 1.99.

Akili (NASDAQ:AKLI) last announced its earnings results on Thursday, February 29th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.12. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $1.07 million. Akili had a negative return on equity of 76.34% and a negative net margin of 3,545.47%. As a group, equities research analysts expect that Akili will post -0.53 earnings per share for the current fiscal year.

Akili Company Profile

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.